EUVIMEDEUVIMED entdecken
Multizentrische Studie

Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors

Kellye Eagan, Charlotte Bolch iD, Elizabeth Van Dril iD, Christie Schumacher iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025

DOI: 10.1002/phar.70006 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Kellye Eagan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Riverside Medical Center, Kankakee, Illinois, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Potassium. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objective The primary objective of this study was to determine if there was a significant change in potassium levels with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor therapy in people with type 2 diabetes (T2D). A co‐primary objective was to evaluate which factors may predispose a patient to changes in potassium levels.

Design

Multicenter retrospective cohort chart review. Data Source Study patients were identified through an electronic medical record‐generated report if they had T2D and were prescribed an SGLT2 inhibitor from January 2013 to September 2019. Patients Patients were included if they had T2D, were receiving care at Advocate Medical Group, and were confirmed to have taken one of the four SGLT2 inhibitors available at the time of study approval, canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin, for at least 7 days. Patients were excluded if they did not have a basic metabolic panel or comprehensive metabolic panel recorded 1 year prior to or 6 months after SGLT2 inhibitor therapy initiation.

Results

Data extraction from the electronic medical record identified 6425 patients receiving an SGLT2 inhibitor, of which 1926 met inclusion criteria. The SGLT2 inhibitor most prescribed was canagliflozin (43.7%), followed by empagliflozin (36.9%) and dapagliflozin (19.4%). Concomitant baseline medications were thiazide diuretics (27.5%); angiotensin‐converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor‐neprilysin inhibitors (72.1%); and/or mineralocorticoid receptor antagonists (27.2%). A statistically significant change in potassium levels was found with dapagliflozin ( p = 0.018); albeit not clinically significant. No other statistically significant changes or patterns were identified. The overall mean change in serum potassium from baseline was 0.021 mmol/L within 3 months; 0.007 mmol/L from 3 to 5.9 months; −0.017 mmol/L within 6–12 months; and 0.004 mmol/L after more than 12 months.

Conclusions

No clinically significant increase or decrease in potassium levels was observed upon initiation of SGLT2 inhibitor therapy in patients with T2D. This was consistent across background medication use and patient‐specific factors. Baseline potassium should not be a factor in initiating SGLT2 inhibitor therapy, if clinically indicated, in patients with T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2PotassiumHumansRetrospective StudiesMaleFemaleMiddle AgedAgedCanagliflozinBenzhydryl CompoundsGlucosidesHypoglycemic AgentsCohort Studies

Stichwörter der Autor:innen

adverse drug reactionsdiabeteshyperkalemiahypokalemiapotassiumsodium‐glucose transporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsPotassiumdapagliflozinCanagliflozinBenzhydryl CompoundsGlucosidesHypoglycemic Agentsempagliflozin

Autor:innen und Institutionen

  • Riverside Medical Center, Kankakee, Illinois, USA.
  • Midwestern University Office of Research and Sponsored Programs, Glendale, Arizona, USA.
  • University of Illinois Chicago Herbert M. And Carol H. Retzky College of Pharmacy, Chicago, Illinois, USA.
  • Midwestern University College of Pharmacy, Downers Grove Campus, Downers Grove, Illinois, USA.
  • Advocate Health, Chicago, Illinois, USA.

ORCID-Profile: Charlotte Bolch, Elizabeth Van Dril, Christie Schumacher

Zitieren

APA

Eagan, K., Bolch, C., Van Dril, E., & Schumacher, C. (2025). Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70006

Vancouver

Eagan K, Bolch C, Van Dril E, Schumacher C. Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70006

BibTeX
@article{Eagan2025,
  author = {Eagan, Kellye and Bolch, Charlotte and Van Dril, Elizabeth and Schumacher, Christie},
  title = {Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  doi = {10.1002/phar.70006}
}
Kostenlos starten →